| GYNECOLOGY (uterine, ovary, cervix) PROTOCOL DETAILS |
PROTOCOL TITLE | DISEASE SITE |
|---|---|---|
Principal Investigator: Peter Argenta Contact: Sharon Donnelly or Marva Bohen info@cancer.umn.edu (612) 624-2620 |
A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxrorubicin (Doxil/Caelyx) in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer (Study No. CEPO906A2303) | Ovarian, Fallopian, Primary Peritoneal |
Principal Investigator: Linda Carson Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
GOG 0212: A Randomized Phase Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) Versus No Treatment Until Documented Relapse in Women with Response to Primary Platinum/Taxane Chemotherapy | |
Principal Investigator: Levi Downs Contact: Sharon Donnelly or Marva Bohen info@cancer.umn.edu (612) 624-2620 |
WCC #45: Prolonged Venous Thromboembolism Prophylaxis with Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial | |
Principal Investigator: Levi Downs Contact: Sharon Donnelly or Marva Bohen info@cancer.umn.edu (612) 624-2620 |
A Multi-Center, Double-Blinded, Randomized, Placebo-Controlled Study of ZYC101a in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN2/3) of the Uterine Cervix | Uterine, Cervical |
Principal Investigator: Levi Downs Contact: Sharon Donnelly or Marva Bohen info@cancer.umn.edu (612) 624-2620 |
WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer | Cervical |
Principal Investigator: Melissa Geller Contact: Deborah Biegert biege001@umn.edu 612-624-8647 |
WCC 38 A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy then Cobnsolidation Chemotherapy with Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer | Uterine |
Principal Investigator: Patricia Judson Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
GOG 209 Randomized Phase III Trial of Doxorubicin/ Cisplatin/ Paclitaxel and G-CSF vs. Carboplatin/ Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer | Uterine |
Principal Investigator: Patricia Judson Contact: Melissa Spence spenc206@umn.edu (612) 624-2620 |
A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma (AVF4095g) | Ovarian, Fallopian, Primary Peritoneal |
Principal Investigator: Patricia Judson Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
GOG 0218: A Phase III Trial of Carboplatin and Paclitaxel plus Placebo Versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab followed by Placebo versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Peritoneal Primary Cancer | Ovarian, Primary Peritoneal |
| Principal Investigator: Amy Skubitz Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
Diagnostic Markers for Ovarian Cancer | Ovary |
| Principal Investigator: Melissa Geller Contact: Linda Kruse kruse004@umn.edu 612-624-9497 |
WCC52: Alterations in serum serotonin levels, as a mechanism for chemotherapy induced constipation. | Ovary |
| Principal Investigator: Patricia Judson Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
WCC33: Outcomes in Ovarian Cancer Patients Using Complimentary Alternative Modalities | Ovary |
| Principal Investigator: Linda Carson Contact: Deborah Biegert biege001@umn.edu 612-624-8647 |
A non-interventional prospective study of the accuracy of the Precision Therapeutics, Inc. chemoresponse assay in patients with recurrent epithelial ovarian or peritoneal cancer. | Ovary |
| Principal Investigator: Melissa Geller Contact: Dixie Lewis lewis029@umn.edu 612-624-0104 |
MT2007-19R: Allogeneic natural killer cells in patients with recurrent ovarian cancer. | Ovary |
| Principal Investigator: Patricia Judson Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
A molecular staging study of endometrial carcinoma. | Endometrial |
| Principal Investigator: Patricia Judson Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
GOG 0173: Intraoperative lymphatic mapping and sentinel node (SN) identification in patients with squamous cell carcinoma of the vulva. | Vulvar |
| Principal Investigator: Patricia Judson Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
GOG 0205: A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally advanced squamous cell carcinoma of the vulva. | Vulvar |
| Principal Investigator: Patricia Judson Contact: Suann Mitchell mitch016@umn.edu 612-624-1919 |
GOG 0222: Prospective evaluation of pelvic exenteration in patients with recurrent cervical cancer. | Cervical |
If interested in these active clinical trials or have any questions, contact Suann Mitchell, RN at mitch016@umn.edu.
What's Inside | ||
| ||
Related Links | ||
| ||